Trial Profile
Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs T-cell vaccine AlloVax (Primary) ; T-cell vaccine-AlloStim; T-cell vaccine-AlloStim
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Immunovative Therapies
- 17 Jan 2020 Status changed from recruiting to completed.
- 18 Jan 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
- 10 Jul 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.